Niagen Bioscience Inc (NAGE)

$7.38 0.00 (N/A)
Market Cap 573.80M
Revenue (ttm) 99.60M
Net Income (ttm) 8.55M
EPS (ttm) N/A
PE Ratio 172.25
Forward PE 55.87
Profit Margin 8.58%
Debt to Equity Ratio 0.00
Volume 308,100
Avg Vol 1,031,450
Day's Range N/A - N/A
Shares Out 77.75M
Stochastic %K 97%
Beta 2.18
Analysts Strong Sell
Price Target $9.03

Latest News on NAGE

Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs

Apr 7, 2025, 10:32 PM EDT - 18 days ago

Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs

Niagen Bioscience Confirms Its Operations Remain Resilient Amid New Tariff Developments

Apr 7, 2025, 8:32 AM EDT - 18 days ago

Niagen Bioscience Confirms Its Operations Remain Resilient Amid New Tariff Developments

Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms

Mar 20, 2025, 8:34 AM EDT - 5 weeks ago

Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms

ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision Science

Mar 19, 2025, 8:34 AM EDT - 5 weeks ago

ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision Science

ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025

Mar 13, 2025, 8:34 AM EDT - 6 weeks ago

ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025

ChromaDex to Present at the 37th Annual Roth Conference

Mar 11, 2025, 4:04 PM EDT - 6 weeks ago

ChromaDex to Present at the 37th Annual Roth Conference

ChromaDex Capitalizes On Longevity Boom But Valuation Remains High

Mar 6, 2025, 10:30 AM EST - 7 weeks ago

ChromaDex Capitalizes On Longevity Boom But Valuation Remains High

ChromaDex Corporation (CDXC) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 8:53 PM EST - 7 weeks ago

ChromaDex Corporation (CDXC) Q4 2024 Earnings Call Transcript

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results

Mar 4, 2025, 4:02 PM EST - 7 weeks ago

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results

ChromaDex to Report Fourth Quarter and Fiscal Year 2024 Financial Results on Tuesday, March 4, 2025

Feb 25, 2025, 4:07 PM EST - 2 months ago

ChromaDex to Report Fourth Quarter and Fiscal Year 2024 Financial Results on Tuesday, March 4, 2025

ChromaDex to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Jan 6, 2025, 8:32 AM EST - 3 months ago

ChromaDex to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products Category

Dec 3, 2024, 8:34 AM EST - 5 months ago

ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products Category

ChromaDex's Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology's Inaugural Longevity Supplement

Nov 14, 2024, 8:32 AM EST - 5 months ago

ChromaDex's Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology's Inaugural Longevity Supplement

ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide

Nov 7, 2024, 8:32 AM EST - 6 months ago

ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide

ChromaDex Corporation (CDXC) Q3 2024 Earnings Call Transcript

Nov 1, 2024, 2:48 PM EDT - 6 months ago

ChromaDex Corporation (CDXC) Q3 2024 Earnings Call Transcript

ChromaDex Corporation Reports Third Quarter 2024 Financial Results

Oct 31, 2024, 4:04 PM EDT - 6 months ago

ChromaDex Corporation Reports Third Quarter 2024 Financial Results

ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024

Oct 28, 2024, 8:32 AM EDT - 6 months ago

ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024

ChromaDex to Participate in the 17th Annual LD Micro Main Event

Oct 23, 2024, 8:34 AM EDT - 6 months ago

ChromaDex to Participate in the 17th Annual LD Micro Main Event

Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN)

Oct 15, 2024, 8:32 AM EDT - 6 months ago

Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN)

ChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor Conference

Sep 26, 2024, 4:12 PM EDT - 7 months ago

ChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor Conference

ChromaDex Appoints Ozan Pamir as Chief Financial Officer

Sep 20, 2024, 8:32 AM EDT - 7 months ago

ChromaDex Appoints Ozan Pamir as Chief Financial Officer

ChromaDex Announces Expansion of Pharmaceutical-Grade Niagen® IV and Injection Offerings to Additional Leading Wellness Clinics

Sep 10, 2024, 8:32 AM EDT - 8 months ago

ChromaDex Announces Expansion of Pharmaceutical-Grade Niagen® IV and Injection Offerings to Additional Leading Wellness Clinics

ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions

Sep 9, 2024, 8:34 AM EDT - 8 months ago

ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions

ChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow Series On Thursday, August 29, 2024

Aug 23, 2024, 8:34 AM EDT - 8 months ago

ChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow Series On Thursday, August 29, 2024

ChromaDex Secures U.S. Patent for the Composition of Matter of Salt Forms of NMNH (Dihydronicotinamide Mononucleotide), a Precursor to NAD+

Aug 19, 2024, 8:32 AM EDT - 8 months ago

ChromaDex Secures U.S. Patent for the Composition of Matter of Salt Forms of NMNH (Dihydronicotinamide Mononucleotide), a Precursor to NAD+

ChromaDex Corporation Reports Second Quarter 2024 Financial Results

Aug 7, 2024, 4:04 PM EDT - 9 months ago

ChromaDex Corporation Reports Second Quarter 2024 Financial Results

ChromaDex to Present at Canaccord Genuity's 44th Annual Growth Conference

Aug 5, 2024, 8:32 AM EDT - 9 months ago

ChromaDex to Present at Canaccord Genuity's 44th Annual Growth Conference

ChromaDex to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024

Jul 24, 2024, 8:34 AM EDT - 9 months ago

ChromaDex to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024

ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively to Health Care Practitioners (HCPs)

Jul 23, 2024, 8:32 AM EDT - 9 months ago

ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively to Health Care Practitioners (HCPs)

ChromaDex Appoints Carlos Lopez as Senior Vice President, General Counsel

Jul 22, 2024, 8:34 AM EDT - 9 months ago

ChromaDex Appoints Carlos Lopez as Senior Vice President, General Counsel

ChromaDex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen® Will Debut at Leading Wellness Clinics in August

Jul 16, 2024, 8:34 AM EDT - 10 months ago

ChromaDex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen® Will Debut at Leading Wellness Clinics in August

ChromaDex to Join Russell 2000® Index

Jul 1, 2024, 8:32 AM EDT - 10 months ago

ChromaDex to Join Russell 2000® Index

ChromaDex: Looking To Take The Big Step Into Pharma

Jun 26, 2024, 12:20 PM EDT - 10 months ago

ChromaDex: Looking To Take The Big Step Into Pharma

Milestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD)

Jun 24, 2024, 8:32 AM EDT - 10 months ago

Milestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD)

ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC)

Jun 13, 2024, 8:32 AM EDT - 11 months ago

ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC)

ChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT)

Jun 7, 2024, 8:34 AM EDT - 11 months ago

ChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT)

ChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow on Tuesday, June 11, 2024

Jun 4, 2024, 8:32 AM EDT - 11 months ago

ChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow on Tuesday, June 11, 2024

ChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

May 23, 2024, 8:34 AM EDT - 1 year ago

ChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

ChromaDex's Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year Award

May 22, 2024, 8:32 AM EDT - 1 year ago

ChromaDex's Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year Award

ChromaDex Corporation (CDXC) Q1 2024 Earnings Call Transcript

May 8, 2024, 8:26 PM EDT - 1 year ago

ChromaDex Corporation (CDXC) Q1 2024 Earnings Call Transcript

ChromaDex Corporation Reports First Quarter 2024 Financial Results

May 8, 2024, 4:04 PM EDT - 1 year ago

ChromaDex Corporation Reports First Quarter 2024 Financial Results

ChromaDex's NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy Supplement

Apr 30, 2024, 8:32 AM EDT - 1 year ago

ChromaDex's NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy Supplement

ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe®

Apr 25, 2024, 8:34 AM EDT - 1 year ago

ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe®

ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024

Apr 24, 2024, 8:34 AM EDT - 1 year ago

ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024

ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market

Apr 23, 2024, 8:32 AM EDT - 1 year ago

ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market

ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program

Mar 26, 2024, 8:32 AM EDT - 1 year ago

ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program

ChromaDex Corporation (CDXC) Q4 2023 Earnings Call Transcript

Mar 6, 2024, 11:11 PM EST - 1 year ago

ChromaDex Corporation (CDXC) Q4 2023 Earnings Call Transcript

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results

Mar 6, 2024, 4:04 PM EST - 1 year ago

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results

ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024

Feb 21, 2024, 8:32 AM EST - 1 year ago

ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024

ChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow on Monday, February 12, 2024

Feb 5, 2024, 8:32 AM EST - 1 year ago

ChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow on Monday, February 12, 2024